Upregulation of Mcl-1 inhibits JQ1-triggered anticancer activity in hepatocellular carcinoma cells

Biochemical and Biophysical Research Communications

Volumn 495, Issue 4, 2018, Pages 2456-2461

  Zhang, Hua Peng ^a,b,c   Li, Gong Quan ^a,b,c   Zhang, Yi ^a,b   Guo, Wen Zhi ^a,b,c   Zhang, Jia Kai ^a,b,c   Li, Jie ^a,b,c   Lv, Jian Feng ^a,b,c   Zhang, Shui Jun ^a,b,c  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b Henan Universities   (China)

^c Henan Key Laboratory of Digestive Organ Transplantation   (China)

Author keywords

Apoptosis; BET inhibitor; Hepatocellular carcinoma; Mcl 1

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; CASPASE 3; FLAVOPIRIDOL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN MCL 1; (+)-JQ1 COMPOUND; ANTINEOPLASTIC AGENT; AZEPINE DERIVATIVE; BROMODOMAIN AND EXTRA-TERMINAL DOMAIN PROTEIN, HUMAN; PROTEIN; TRIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENE EXPRESSION; HEPATOCELLULAR CARCINOMA CELL LINE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA SEQUENCE; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HEP-G2 CELL LINE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AZEPINES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEINS; TRIAZOLES; UP-REGULATION;

EID: 85039548629     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2017.12.153     Document Type: Article

References (18)

1. Campbell, R.M., Tummino, P.J., Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J. Clin. Invest. 124 (2014), 64–69.
2. Barbieri, I., Cannizzaro, E., Dawson, M.A., Bromodomains as therapeutic targets in cancer. Brief Funct. Genom. 12 (2013), 219–230.
3. Chaidos, A., Caputo, V., Karadimitris, A., Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence. Ther. Adv. Hematol. 6 (2015), 128–141.
4. Shao, Q., Kannan, A., Lin, Z., Stack, B.J., Suen, J.Y., Gao, L., BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo. Canc. Res. 74 (2014), 7090–7102.
5. Loven, J., Hoke, H.A., Lin, C.Y., Lau, A., Orlando, D.A., Vakoc, C.R., Bradner, J.E., Lee, T.I., Young, R.A., Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153 (2013), 320–334.
6. Wu, Z., Hu, Z., Han, X., Li, Z., Zhu, Q., Wang, Y., Zheng, Q., Yan, J., The BET-Bromodomain Inhibitor JQ1 synergized ABT-263 against colorectal cancer cells through suppressing c-Myc-induced miR-1271-5p expression. Biomed. Pharmacother. 95 (2017), 1574–1579.
7. Ishida, C.T., Shu, C., Halatsch, M.E., Westhoff, M.A., Altieri, D.C., Karpel-Massler, G., Siegelin, M.D., Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma. Oncotarget 8 (2017), 37140–37153.
8. Berthon, C., Raffoux, E., Thomas, X., Vey, N., Gomez-Roca, C., Yee, K., Taussig, D.C., Rezai, K., Roumier, C., Herait, P., Kahatt, C., Quesnel, B., Michallet, M., Recher, C., Lokiec, F., Preudhomme, C., Dombret, H., Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol. 3 (2016), e186–e195.
9. Andrieu, G., Belkina, A.C., Denis, G.V., Clinical trials for BET inhibitors run ahead of the science. Drug Discov. Today Technol. 19 (2016), 45–50.
10. Li, G.Q., Guo, W.Z., Zhang, Y., Seng, J.J., Zhang, H.P., Ma, X.X., Zhang, G., Li, J., Yan, B., Tang, H.W., Li, S.S., Wang, L.D., Zhang, S.J., Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression. Oncotarget 7 (2016), 2462–2474.
11. Zhang, S.J., Li, G.Q., Ma, X.X., Wang, Y., Liu, G.Z., Feng, L.S., Zhao, Y.F., Zhang, G., Wu, Y., Ye, X.X., Qin, B.M., Lu, J.F., Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1. Cell Signal. 24 (2012), 1803–1809.
12. Kim, Y., Park, S.E., Moon, J.W., Kim, B.M., Kim, H.G., Jeong, I.G., Yoo, S., Ahn, J.B., You, D., Pak, J.H., Kim, S., Hwang, J.J., Kim, C.S., Downregulation of androgen receptors by NaAsO2 via inhibition of AKT-NF-kappaB and HSP90 in castration resistant prostate cancer. Prostate 77 (2017), 1128–1136.
13. Dontu, G., Abdallah, W.M., Foley, J.M., Jackson, K.W., Clarke, M.F., Kawamura, M.J., Wicha, M.S., In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17 (2003), 1253–1270.
14. Cho, S.J., Kim, Y.J., Surh, Y.J., Kim, B.M., Lee, S.K., Ibulocydine is a novel prodrug Cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells. J. Biol. Chem. 286 (2011), 19662–19671.
15. Dai, X., Gan, W., Li, X., Wang, S., Zhang, W., Huang, L., Liu, S., Zhong, Q., Guo, J., Zhang, J., Chen, T., Shimizu, K., Beca, F., Blattner, M., Vasudevan, D., Buckley, D.L., Qi, J., Buser, L., Liu, P., Inuzuka, H., Beck, A.H., Wang, L., Wild, P.J., Garraway, L.A., Rubin, M.A., Barbieri, C.E., Wong, K.K., Muthuswamy, S.K., Huang, J., Chen, Y., Bradner, J.E., Wei, W., Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat. Med. 23 (2017), 1063–1071.
16. Kurimchak, A.M., Shelton, C., Duncan, K.E., Johnson, K.J., Brown, J., O'Brien, S., Gabbasov, R., Fink, L.S., Li, Y., Lounsbury, N., Abou-Gharbia, M., Childers, W.E., Connolly, D.C., Chernoff, J., Peterson, J.R., Duncan, J.S., Resistance to BET bromodomain inhibitors is mediated by kinome reprogramming in ovarian cancer. Cell Rep. 16 (2016), 1273–1286.
17. Kumar, K., Raza, S.S., Knab, L.M., Chow, C.R., Kwok, B., Bentrem, D.J., Popovic, R., Ebine, K., Licht, J.D., Munshi, H.G., GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. Sci. Rep., 5, 2015, 9489.
18. Sieghart, W., Losert, D., Strommer, S., Cejka, D., Schmid, K., Rasoul-Rockenschaub, S., Bodingbauer, M., Crevenna, R., Monia, B.P., Peck-Radosavljevic, M., Wacheck, V., Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J. Hepatol. 44 (2006), 151–157.